Search research articles
Contact Us
Filters
Showing results (171-180 of 377) with videos related to
Page
of 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
Otto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)
|
February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial
Sibylle Loibl, Michael Untch, Jens Huober, et al.
Clinical Laboratory
|
February 21, 2003
Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients
Petra Stieber, Rafael Molina, Daniel W Chan, et al.
Journal of the National Cancer Institute
|
August 5, 2004
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
Gottfried E Konecny, Christoph Thomssen, Hans Joachim Lück, et al.
Journal of the National Cancer Institute
|
June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Rebecca Dent, Javier Cortés, Lajos Pusztai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancer
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups
Michael Untch, Peter A Fasching, Gottfried E Konecny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study
Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.
Clinical Epigenetics
|
October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
Philipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Page
of 38
Search research articles
Search
Showing results (171-180 of 377) with videos related to
Sort By:
Page
of 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2013
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
Otto Metzger-Filho, Marion Procter, Evandro de Azambuja, et al.
Lancet (London, England)
|
February 21, 2017
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron, Martine J Piccart-Gebhart, Richard D Gelber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial
Sibylle Loibl, Michael Untch, Jens Huober, et al.
Clinical Laboratory
|
February 21, 2003
Clinical evaluation of the Elecsys CA 15-3 test in breast cancer patients
Petra Stieber, Rafael Molina, Daniel W Chan, et al.
Journal of the National Cancer Institute
|
August 5, 2004
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer
Gottfried E Konecny, Christoph Thomssen, Hans Joachim Lück, et al.
Journal of the National Cancer Institute
|
June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study
Rebecca Dent, Javier Cortés, Lajos Pusztai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Response-guided neoadjuvant chemotherapy for breast cancer
Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 27, 2011
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups
Michael Untch, Peter A Fasching, Gottfried E Konecny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2012
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study
Valentina Guarneri, Antonio Frassoldati, Alberto Bottini, et al.
Clinical Epigenetics
|
October 4, 2021
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status
Philipp Jurmeister, Karsten Weber, Sonia Villegas, et al.
Page
of 38